Stocksigma LogoStocksigma Logo

Dr. Reddy’s Secures Brazil Approval for Generic Semaglutide Injection

Dr. Reddy’s Laboratories received marketing authorization from Brazil’s ANVISA on 5th Nov'26 for generic semaglutide injection to treat type 2 diabetes

Dr. Reddy’s Secures Brazil Approval for Generic Semaglutide Injection

Dr Reddys Laboratories Ltd · Press Release · 05 Nov 2026, 3:17 pm

Dr. Reddy’s Secures Brazil Approval for Generic Semaglutide Injection Dr. Reddy’s Laboratories received marketing authorization from Brazil’s ANVISA on 5th Nov'26 for generic semaglutide injection to treat type 2 diabetes. The product will launch in Brazil via a partnership with Aché as a once-weekly pre-filled pen across two presentations (2 mg/1.5 mL and 4 mg/3 mL). The authorization expands the company's footprint in Brazil, where the semaglutide market for diabetes is estimated at approximately USD 244.6 million (IQVIA, MAT Sep'26), addressing a patient base of 16.6 million adults.

Original exchange filing (PDF)

More announcements from Dr Reddys Laboratories Ltd

All Dr Reddys Laboratories Ltd announcements